Genzyme Corporation et al v. Novartis Gene Therapies, Inc. et al > Summary
Court Case Number 1:23-cv-00554
Filing Date May 19, 2023
Termination Date Feb 14, 2024
Court Delaware District Court
Status Dismissed - Settled
JudgesRichard G. Andrews
Plaintiff Attorneys
14Sanofi
Attorney Name: David E. Wilks
Wilks Law Firm
Sanofi
Attorney Name: Amanda K. Antons
Dechert
Sanofi
Attorney Name: Brian M. Goldberg
Dechert
Sanofi
Attorney Name: Daniel Roberts
Dechert
Sanofi
Attorney Name: Donald C. Vavala III
Wilks Law Firm
Sanofi
Attorney Name: Jonathan D. Loeb
Dechert
Sanofi
Attorney Name: Judah Bellin
Dechert
Sanofi
Attorney Name: Katherine A. Helm
Dechert
Sanofi
Attorney Name: Martin J. Black
Dechert
Sanofi
Attorney Name: Noah M. Leibowitz
Dechert
Sanofi
Attorney Name: Pejmon Pashai
Dechert
Sanofi
Attorney Name: Scott Czerwonka
Wilks Law Firm
Sanofi
Attorney Name: Sharon K. Gagliardi
Dechert
Sanofi
Attorney Name: Shyam Shanker
Dechert
Defendant Attorneys
6Novartis Gene Therapies, Inc.
Attorney Name: Daniel M. Silver
McCarter & English
Novartis Gene Therapies, Inc.
Attorney Name: Cora R. Holt
Finnegan, Henderson, Farabow, Garrett & Dunner
Novartis Gene Therapies, Inc.
Attorney Name: Jeffrey D. Smyth
Finnegan, Henderson, Farabow, Garrett & Dunner
Novartis Gene Therapies, Inc.
Attorney Name: John D. Livingstone
Finnegan, Henderson, Farabow, Garrett & Dunner
Novartis Gene Therapies, Inc.
Attorney Name: M. David Weingarten
Finnegan, Henderson, Farabow, Garrett & Dunner
Related Patents
| Doc No | Title | Issue date |
|---|---|---|
| 10429288 | Analytical ultracentrifugation for characterization of recombinant viral particles | Oct 1, 2019 |
| 09051542 | Compositions and methods to prevent AAV vector aggregation | Jun 9, 2015 |
| 08093054 | Metabolically activated recombinant viral vectors and methods for their preparation and use | Jan 10, 2012 |
